Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal.
With its proprietary H-Guard™ technology, Invizius is addressing the side effects of hemodialysis to help patients feel better, and suffer fewer cardiovascular complications.
The business is a spin-out from world-class research carried out at the University of Edinburgh, Scotland, and has been funded by Scottish Enterprise's prestigious High-Growth Spinout Programme.
A dialyzer priming solution designed to allow hemodialysis patients to live longer, feel better, and suffer fewer cardiovascular complications
Our proprietary H-Guard™ coating is a potent anti-inflammatory and anti-coagulant, which cloaks surfaces from the human immune system
Our team combines world-leading scientists with experienced life science executives and entrepreneurs